Theravance Biopharma (TBPH) Common Equity (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Common Equity data on file, last reported at $290.6 million in Q1 2026.

• Common Equity for Q1 2026 came in at $290.6 million, up 75.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $290.6 million (up 75.07% YoY), and the FY2025 annual result was $296.7 million, up 69.03% from the prior year.
• Common Equity fell to $290.6 million in Q1 2026 per TBPH's latest filing, from $296.7 million in the prior quarter.
• Over five years, Common Equity peaked at $480.6 million in Q3 2022 and troughed at -$351.4 million in Q1 2022.
• A 5-year average of $194.2 million and a median of $224.8 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity jumped 248.51% in 2022, then sank 51.79% in 2023.
• A 5-year view of Common Equity shows it stood at $441.8 million in 2022, then slumped by 51.79% to $213.0 million in 2023, then fell by 17.58% to $175.5 million in 2024, then soared by 69.03% to $296.7 million in 2025, then declined by 2.07% to $290.6 million in 2026.
• Business Quant data shows TBPH's Common Equity at $290.6 million in Q1 2026, $296.7 million in Q4 2025, and $232.7 million in Q3 2025.